PAI-2
SERPINB2proteinPAI-2 regulates fibrinolysis by inhibiting tissue plasminogen activator and urokinase, modulating thrombus stabilization and resolution.
Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencemedium
RationaleFibrinolytic pathway regulation; plasmin inhibition and thrombus turnover.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000197632
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I56
C — confounder / Type-II47
A — assay feasibility68
E — evidence strength23
T1DI (composite)9
Specificity differential (R−C)+9.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease.Thrombosis and haemostasis · 2022 · PMID 36588289 · doi